hiv help off-set hcv eros gilead
come lower pt
gilead report product revenu beat consensu
sequenti non-gaap net incom non-gaap
ep miss consensu higher expens quarter
cog relat inventori reserv hepat viru hcv well
increas opex contribut bottom-lin miss compani announc
increas dividend prior quarter
gilead end year cash
hiv revenu continu grow
prior quarter growth hiv expect continu particularli around pre-
exposur prophylaxi prep help off-set continu revenu
declin hcv expect
guidanc model chang product revenu non-
adjust guidanc point essenti flat product revenu
vs lower non-gaap ep estim
price target lower
focu next chapter ceo daniel day set take helm march
much focu perspect readout nash expect
selonsertib potenti nda file addit
two studi filgotinib expect readout finch
also expect cash like strateg focu
expand pipelin
year ahead transit next chapter hepat viru hcv revenu
stabil gilead hiv market domin hiv patient
patient take antiretrovir continu domin hiv space gilead
could face headwind compet hiv regimen though could potenti
remedi growth pre-exposur prophylaxi prep prep individu
us take truvada cdc estim peopl may benefit
prep regimen descovi prep phase data expect question
come next car-t cell therapi revenu yescarta continu
slow steadi climb upward cell therapi pipelin still near-term
growth driver much focu like turn pipelin includ late-stag asset
nash inflammatori diseas expect cash
activ expand pipelin like strateg focu
pipelin watch nash inflammatori diseas
agonist inhibitor focu selonsertib drug two
pivot trial read fibrosi
collabor scholar nr yuhan ks nr
inflammatori diseas focu filgotinib rheumatoid arthriti ra
finch finch phase studi expect read manta
still limit factor though enrol pick manta provid
safeti data specif around male infertil filgotinib also move forward
crohn ulcer coliti uc well multipl indic
franchis gilead
exhibit guidanc issu
exhibit us market dynam hiv
exhibit gilead us share treatment nave hiv patient
exhibit descovy-bas regimen continu overtak tdf
exhibit biktarvi success hiv product launch us
exhibit biktarvi move us treatment patient
exhibit truvada prep continu grow us
exhibit descovi prep trial read
exhibit hcv patient initi sovaldi-bas regimen
exhibit data readout ahead
pipelin asset focu
exhibit target multipl pathway nash
exhibit selonsertib monotherapi studi readout
exhibit on-going atla combin studi advanc nash
exhibit phase data rheumatoid arthriti expect filgotinib
exhibit develop strategi inflammatori diseas
exhibit phase trial data phase trial report data rheumatoid arthriti patient
multipl drug failur trial achiev primari rank secondari endpoint
exhibit partnership activ expand pipelin
exhibit mileston pipelin area
thousand except per share data
contract revenu
cog associ car-t
royalti merck us sale harvoni sovaldi
interest incom net
net loss attribut non control interest
net incom attribut gilead
basic ep attribut gilead sharehold
gaap dilut ep attribut gilead sharehold
compani report maxim group estim
